Dossier - Page 1 - FirstWord Reports

Learn More Adherence – What Do Pharma Really Know

Adherence – What Do Pharma Really Know The entire industry is talking about patient centricity but are the right steps being taken to address the most fundamental patient issue: non-adherence? Is ‘big...

Compare
Learn More Biosimilars Real World Evidence: Proving the point

Biosimilars Real World Evidence: Proving the point Biosimilar manufacturers face an uphill struggle to fully mobilise their product portfolio. Against a background of aggressive defence strategies by originator...

Compare
Learn More MSL stakeholder engagement: meeting expectations

MSL Stakeholder Engagement–Meeting Expectations In this report, FirstWord identifies practical solutions to the stakeholder engagement challenges faced by medical science liaisons (MSLs) teams in 2017. Discover...

Compare
Learn More What do Patients want from Pharma?: The Real Patient-Centric Perspective

What do Patients want from Pharma? How can pharma leverage patient insights to deliver the support they want? Is patient centricity coming of age? The patient voice is becoming increasingly influential and...

Compare
Learn More Evidence Matters: Why Pharma Needs to Get Serious about Data

Real World Evidence: Creating a forward-focused strategy In today’s highly scrutinised drugs marketplace, pockets continue to be squeezed and the list of demands from every quarter lengthens. Against this...

Compare
Learn More The Future of Biosimilars in Europe

Education is top priority as biosimilar mAbs enter the market With the recent approval of Celltrion’s Truxima, all eyes are on biosimilar oncology monoclonal antibodies (mAbs). Experts say they’re the next...

Compare
Learn More Biomarkers and Companion Diagnostics - Payer views

Winning Payer Support for Companion Diagnostics & Biomakers How can you positively influence payer attitudes to biomarkers and companion diagnostics (CDx)? Biomarkers and CDx are critical to realising the...

Compare
Learn More Charting MSL Activity and Performance (2017)

A unique survey-based report providing key insights and actionable intelligence about MSL activity and performance. Charting MSL Activity and Performance (2017) distils key findings from one of the most comprehensive...

Compare
Learn More Real World Data: Meeting Payer Needs

How to adjust your Real World Data provision to address the real needs of payers Drug costs are spiralling upwards and so too are frustration levels. Payers with stretched budgets are still struggling to make the case...

Compare
Learn More How Payers Want to Work With Pharma

How to effectively engage US and EU payers You’re speaking to payers, but are they listening? Do you really understand their needs and concerns? Is your approach to payer negotiations getting your...

Compare
Learn More Medical Affairs in Orphan Drugs

Orphan drugs: Is your medical affairs team leading the fray or lagging behind? Traditional commercial models simply don’t work for orphan drugs, not least because the physician and patient populations are so...

Compare
Learn More Pulling the Data Puzzle Together: Being Payer-Centric

Mapping data with payer needs. How to solve the data puzzle. Everyone is talking about data. What’s being collected; how robust is it; what does it prove; who should be told? From the all-important payer...

Compare
Learn More Charting the Orphan Drug Development Pipeline

Which are the most exciting areas of orphan drug research and where are the best opportunities? Global sales of drugs for orphan indications were estimated to be $114 billion in 2016, with sales forecast to rise to $209...

Compare
Learn More Biosimilars in Emerging Markets (2017)

Biosimilars: Make the most of high risk emerging market opportunities Emerging biosimilars markets are currently a $5billion opportunity with even more growth potential ahead. Lower drug costs and improved patient...

Compare
Learn More Biosimilars: US Payer Perspectives (2017)

Will biosimilar provide a ‘magic bullet’ to drug prices in the US? Payers speak out… Biosimilars continue to be big business in the US, but has progress has been too slow? Not so, argue payers...

Compare
Learn More The Future of Biobetters

Strategies for success in the biobetter market How can you successfully position biobetter products in the increasingly crowded branded biologic/biosimilar space? With the prospect of improving patient adherence,...

Compare
Learn More Real World Data Capabilities: Benchmarking Pharma Companies

Is Real World Data giving your market access the power charge it needs? Real World Data (RWD) and Real World Evidence (RWE) are gaining traction across the industry. The front runners are already exploring new ways to...

Compare
Learn More Overcoming Market Access Barriers to High Value Drugs

Overcoming market access barriers to high-value drugs How can you breakthrough the market access barriers that face high-value oncology and immunotherapy products in the EU5 and US? Pharma faces unprecedented demands...

Compare
Learn More Biosimilars: European Payer Perspectives (2017)

What is the future for biosimilars in the EU? What issues do EU Payers think will impact adoption, pricing and reimbursement of biosimilars? In January 2016 Samsung Bioepis launched Benepali, a biosimilar version of...

Compare
Learn More The Future of Medical Affairs

What are the future opportunities and challenges for medical affairs? As the interface between companies and KOLs, HCPs, payers and patients, medical affairs has grown rapidly in importance. And demands are set to...

Compare

Browse by